A specialty pharmaceutical company has secured $15 million in venture debt backing for its topical gel drug to treat the early stages of mycosis fungoides, a type of non-Hodgkin’s lymphoma.
The investment will go toward operational expenses and commercializing the drug, for which a new drug application (NDA) has been submitted to the U.S. Food and Drug Administration for approval.
The mechlorethamine gel received orphan drug status form European regulators last month, a designation given to drugs for rare diseases that can exempt the company from certain expenses and reduce the cost of research and development.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ceptaris Pharmaceuticals in Malvern, Pennsylvania has received $7.5 million and will be given access to another $7.5 million if the NDA gets approved by U.S. regulators.
Its primary venture capital investors are Osage Ventures, Aperture Venture Partners, BioAdvance, Vivo Ventures, Palo Alto Investors and Burrill & Co.
“We are very pleased with our venture debt relationships with both SVB and Oxford, and the additional capital it provides Ceptaris for pre- and post-launch activities,” said Stephen Tullman, president and CEO at Ceptaris.
Cutaneous T-cell lymphomas account for about 2 percent to 3 percent of non-Hodgkin’s lymphoma cases. The most common form of cutaneous T-cell lymphoma is mycosis fungoides, a slow-growing cancer that starts on the skin.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
